- Conditions
- Kaposi Sarcoma
- Interventions
- Propranolol Hydrochloride
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,207
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency
- Interventions
- Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Denver, Colorado • Washington D.C., District of Columbia + 6 more
- Conditions
- Fanconi Anemia
- Interventions
- Oxandrolone
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lymphoma
- Interventions
- filgrastim, busulfan, melphalan, thiotepa, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
- Interventions
- Blinatumomab Injection
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- cholecalciferol, polymerase chain reaction, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy, immunoscintigraphy
- Dietary Supplement · Genetic · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Sarcoma
- Interventions
- liposomal daunorubicin citrate
- Drug
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Epstein-Barr Virus Infection
- Interventions
- mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 482 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- O6-benzylguanine, carmustine, chemosensitization/potentiation therapy
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
- Interventions
- HBIG, Epivir, Hepsera
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Neuroendocrine Carcinoma of the Skin
- Interventions
- CMF regimen, cyclophosphamide, fluorouracil, methotrexate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
- Conditions
- End Stage Renal Disease on Hemodialysis (Diagnosis)
- Interventions
- HEPLISAV-B®
- Drug
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
- Conditions
- Brain Neoplasms
- Interventions
- Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
- Drug · Radiation · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Tecogalan sodium
- Drug
- Lead sponsor
- Daiichi Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Interventions
- Valacyclovir Hydrochloride
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy, Best Disease, Aniridia, Albinism
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 1 Day to 120 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2054
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Hepatitis B
- Interventions
- Prednisone Priming
- Drug
- Lead sponsor
- Maimonides Medical Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Colitis, HIV Infections
- Interventions
- Ganciclovir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 21 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Ovarian Cancer
- Interventions
- Circulating tumour DNA testing
- Diagnostic Test
- Lead sponsor
- Walter and Eliza Hall Institute of Medical Research
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Aggressive NK-cell Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myeloid/NK-cell Acute Leukemia, Noncutaneous Extranodal Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
- Interventions
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 19 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- music therapy
- Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Topotecan
- Drug
- Lead sponsor
- SmithKline Beecham
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
- Conditions
- Advanced Cancers
- Interventions
- LY2606368
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Essential Thrombocythemia, Extramedullary Plasmacytoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Noncontiguous Stage II Mantle Cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- massage therapy, questionnaire administration, quality-of-life assessment, intervention by caregiver, standard follow-up care
- Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina